Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China

Immuneonco Biopharmaceuticals (HKG:1541) has obtained approval from the National Medical Products Administration of China to conduct a phase III clinical trial of IMM01 (Timdarpacept) in combination w

MT NewswiresMay 17 07:10 ET

Yiming Angko-B (01541.HK): IMM01 (tidapecip) combined with azacitidine was approved by the State Drug Administration to conduct a randomized, double-blind, controlled phase III clinical trial plan

Gelonghui, May 17 | Yiming Angko-B (01541.HK) issued an announcement. The Group was approved by the Drug Evaluation Center of the State Drug Administration (“Drug Evaluation Center”) to conduct a randomized, double-blind, controlled IMM01 (tidapecip) combined with azacitidine phase III clinical trial plan for first-line treatment of high-risk myelodysplastic syndrome (HRMDS). Furthermore, the latest results of the IMM01 (tidapecip) combined with azacitidine phase II clinical trial program have been accepted by the 2024 American Society of Clinical Oncology (“ASC”) to be held in Chicago on June 1, 2024

Gelonghui FinanceMay 17 04:37 ET

宜明昂科-B：2023年報

Futu NewsApr 26 09:49 ET · Announcements

Gelonghui Announcements Selected (Hong Kong Stock) | Xiaopeng Automobile-W (09868.HK) signs strategic cooperation framework agreement with Volkswagen Group on electronic and electrical architecture technology

[Today's Focus] Xiaopeng Motor-W (09868.HK) and Volkswagen Group sign a strategic cooperation framework agreement on electronic and electrical architecture technology Xiaopeng Motor-W (09868.HK) and Volkswagen Group jointly announced that Xiaopeng Motor and Volkswagen Group have signed a strategic cooperation framework agreement on electronic and electrical architecture (“electronic and electrical architecture”) technology. The industry-leading electronic and electrical architecture independently developed by Xiaopeng Motor is the core technology of its vertically integrated software and hardware technology. Thanks to this advanced electronic and electrical architecture, software such as intelligent driving assistance software and connected vehicle operating systems can be decoupled from the underlying hardware and vehicle platform,

Gelonghui FinanceApr 17 11:07 ET

Yiming Angko-B (01541.HK): IMM01 (tidapecip) was approved by the State Drug Administration for phase III clinical trial program

Gelonghui, April 17 | Yiming Angko-B (01541.HK) announced that in April 2024, the Group has obtained approval from the China National Drug Administration for recurrent or refractory (R/R) classic Hodgkin lymphoma (cL) that recurs or progresses after treatment with IMM01 (tidapacept) and tirelizumab in combination therapy with procedural cellular death protein 1 (PD-1) inhibitors. The Group's core product IMM01 (tidapecip) is an innovative targeting differentiation cluster 47 (CD47) molecule. This product is the first to enter China

Gelonghui FinanceApr 17 06:20 ET

Cansino Biotech (06185), the leading healthcare market, surged 15.12%, and Beijing, Guangzhou, and Zhuhai issued pharmaceutical innovation support policies

Jinwu Financial News | The healthcare sector led the market. Hang Seng Healthcare Index rose 1.93%. Among the constituent stocks, Cansino Biotech (06185) rose 15.12%, Junshi Biotech (01877) rose 11.9%, Genting Xinyao (01952) rose 7.8%, Yiming Angke (01541) rose 7.79%, Pharmaceuticals (02268) rose 5.98%, and Tiger Pharmaceuticals (03347) rose 5.8%. According to the news, the Beijing Municipal Medical Security Administration issued “On “Certain Measures to Support the High-Quality Development of Innovative Pharmaceuticals by 9 Departments Including the Beijing Municipal Medical Security Administration” (202

金吾財訊Apr 9 01:59 ET